Table 1. Maximal flow-volume values at baseline, 10 minutes post-treatment and post-5 km time-trial. Data are menas (±SD).
|
|
Placebo |
SAL800 |
SAL1600 |
| Baseline |
FEV1 (l) |
4.6 (.9) |
4.6 (.9) |
4.6 (.9) |
|
Predicted FEV1 (%) |
106.0 (13.5) |
106.1 (14.5) |
106.0 (14.8) |
|
FVC (l) |
5.4 (.9) |
5.3 (1.0) |
5.2 (1.0) |
|
Predicted FVC (%) |
103.4 (12.4) |
102.0 (13.6) |
101.3 (13.4) |
|
FEV1 % |
86.4 (3.4) |
87.4 (3.4) |
87.6 (3.4) |
| Post Salbutamol |
FEV1 (l) |
4.6 (.9) |
4.7 (.9) |
4.7 (.9) |
|
FVC (l) |
5.3 (.9) |
5.3 (.9) |
5.2 (1.0) |
|
FEV1 % |
87.1 (3.4) |
89.1 (4.1) * |
89.4 (4.1) * |
| Post 5 km time-trial |
FEV1 (l) |
4.6 (.9) |
4.7 (1.0) |
4.7 (1.0) |
|
FVC (1) |
5.1 (1.0) |
5.1 (1.0) |
5.1 (1.0) |
|
FEV1 % |
89.9 (5.4) |
91.0 (4.7) |
92.0 (4.7) |
*= significantly greater than PLA.
